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TO THE EDITOR
Chronic mucocutaneous candidiasis dis-
ease (CMCD), first described clinically
in 1969, is characterized by recurrent
or persistent infections of the skin
and mucosae with Candida albicans
with no or a few other clinical manifes-
tations (Kirkpatrick, 2001; Lilic, 2002).
In 2011, Puel et al. (2011) identified the
first inborn errors of IL-17 immunity
underlying CMCD: complete auto-
somal-recessive IL-17RA and partial
autosomal-dominant (AD) IL-17F
deficiencies. AD CMCD has since
been shown to be caused by hetero-
zygous mutations in the coiled-coil
domain of the STAT1 gene (Liu et al.,
2011; Smeekens et al., 2011; van de
Veerdonk et al., 2011; Hori et al.,
2012; Takezaki et al., 2012; Toth
et al., 2012; Solte´sz et al., 2013;
Wang et al., 2013) and accounts for
the majority of cases. All of these
mutations are gain of function (GOF)
and were shown to induce an increa-
sed STAT1 phosphorylation in res-
ponse to IFN-ab, IFN-g and IL-27
due to an impaired nuclear STAT1
dephosphorylation, resulting in a gain
of transcriptional activity (Liu et al.,
2011; Takezaki et al., 2012). More-
over, CMCD patients with STAT1 GOF
mutations showed a highly reduced
number of IL-17-producing CD4þT
cells, as assessed both ex vivo and
after in vitro differentiation of T cells
(Liu et al., 2011; Smeekens et al., 2011;
van de Veerdonk et al., 2011; Takezaki
et al., 2012).
An 8-year-old Tunisian girl, born to
first-cousin parents, was admitted be-
cause of the progressive appearance
of facial scaly plaques that evolved for
2 years. She had a history of an episode
of vulvovaginal candidiasis at the age of
7 years, which was successfully treated.
Examination revealed keratosic erythe-
matous plaques on the cheekbones and
nose, multiple crusted papules on the
upper and lower limbs, a rifle thrush,
a perleche, and a squamo-columnar
crusty cheilitis. The direct mycological
examination showed many filaments
and yeast colonies. The skin biopsy of
facial lesions showed a polymor-
phic inflammatory infiltrate made up of
granulomas and with the presence of
multiple filaments and spores. A stan-
dard staging found multiple candidiasis
lesions of the nose, ear, and esophagus.
The patient recovered after 6 months
of oral treatment with fluconazole.
Because of the disseminated chronic
mucocutaneous candidiasis and the
absence of HIV or immunosuppression,
CMCD was suspected and further inves-
tigations were performed, ruling out a
diagnosis of autoimmune polyendocrine
syndrome or other immunodeficiencies.
The patient is now 13 years old. A
recurrence of candidiasis was observed
but was controlled by anti-fungal treat-
ment. She did not suffer from any other
severe infections, auto-immune mani-
festations, or cerebral aneurysms. She
was the only affected individual in her
family and no familial history was
reported.
Written consent was obtained before
investigation and adherence to the
Declaration of Helsinki Principles was
maintained. The patient’s genomic DNA
sequencing of the STAT1 coiled-coilAccepted article preview online 11 November 2013; published online 12 December 2013
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domain found a heterozygous missense
mutation c.876T4G in exon 7, chan-
ging a leucine to an arginine residue
(p.Leu163Arg) (Figure 1a). This variation
was not found in single-nucleotide poly-
morphism databases (NCBI, UCSC), nor
in a panel of 1,052 the Centre d’Etude
du Polymorphisme Humain and Human
Genome Diversity panels controls, rul-
ing out the possibility of an irrelevant
polymorphism. This private L163R var-
iation was predicted to be probably
damaging by ‘‘POLYphen-2’’ and dama-
ging by ‘‘SIFT’’. The leucine-163 residue
is conserved across species. The patient’s
mother, father, and sister were healthy
and homozygous wild type (WT) for the
STAT1 variant, suggesting that the muta-
tion occurred de novo in a parental germ
line.
We therefore characterized the func-
tional effect of the L163R STAT1 allele
and compared it with that of a WT, two
STAT1 GOF alleles (R274Q and
D165H), and a STAT1 loss-of-function
allele (Y701C) (Liu et al., 2011; Hirata
et al., 2013). We transfected STAT1-
deficient U3C fibrosarcoma cells with
a WT or with STAT1 mutant alleles.
Upon stimulation with IFN-g, cells
transfected with the L163R, R274Q,
or D165H allele responded more
strongly than those transfected with the
WT, mock, or Y701C allele, as shown
by measurement of the induction of
g-activated sequence. The difference
was statistically significant in the
cells expressing the L163R mutation
as compared with WT-expressing cells
(Po0.01; Figure 1b). We therefore
concluded that L163R is a GOF
mutation.
We then evaluated IL-17-producing T
cells ex vivo: the proportion of CD3þ
IL 17Aþ cells in nonadherent PBMCs
was determined by flow cytometry and
whole-blood cell secretion of IL17A,
IL 17F, and IL-22 (data not shown)
was measured by ELISA, as previously
described (Liu et al., 2011). The patient
did not display any defect of IL-17þ
T cells as compared with healthy
controls (Figure 2a and b). In contrast
to these results, the in vitro differentia-
tion of naive CD45RAþ /CD4þ T cells
into IL-17-producing T cells showed a
reduced proportion of IL-17A-producing
cells as well as an impaired secretion of
IL-17A as compared with control
(Figure 2c and d).
Heterozygous STAT1 GOF mutations
causing AD CMCD have been reported
to underlie sporadic and familial traits
(Liu et al., 2011; Smeekens et al., 2011;
van de Veerdonk et al., 2011; Takezaki
et al., 2012; Toth et al., 2012; Solte´sz
et al., 2013; Wang et al., 2013).
Interestingly, this patient was born to
first-cousin parents. Both were healthy
and WT at the STAT1 locus. Therefore,
this case illustrates that sporadic traits
in consanguineous families can be AD
and draws attention to the fact that
AD traits should not be neglected in
countries with high levels of
consanguinity.
Surprisingly, our patient does not dis-
play any abnormality of IL-17-produc-
ing T cells when studied ex vivo.
Unknown compensatory mechanisms
may account for this normal ex vivo
IL-17 production. The age of the patient,
the number of infectious episodes, and
the time of sampling with regard to the
presence of active infection are factors
that may influence this test. Moreover,
the anti-candidiasis treatment and sub-
sequent control of the infection may
have interfered with IL-17-producing
T cells. Further investigations are needed
to assess the effective role of these
factors. Furthermore, this test explores
cells in systemic circulation but not
in the affected tissues, which may be
different. Consequently, the normal
number and function of IL-17-producing
T cells ex vivo does not exclude the
impairment of the development of these
cells in CMCD with STAT1 GOF muta-
tion, as differentiation of the patient’s
naive T cells into IL-17-producing
T cells in vitro was decreased. Thus,
in vitro studies should be included
among screening tests in such patients.
Nevertheless, to better assess the key
mechanisms involved in CMCD, the
impairment of STAT1 signaling should
also be studied at the mucosal T-cell
level. This study suggests that muco-
cutaneous immune response defects,
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Figure 1. Heterozygous gain-of-function (GOF) mutation affecting the STAT1 coiled-coil domain in a
patient with chronic mucocutaneous candidiasis disease (CMCD). (a) STAT1 DNA sequence
electrophoregrams for the patient and a control. (b) Characterization of the L163R STAT1 allele functional
effect. U3C cells were transiently co-transfected for 24 hours with gamma-activated sequence (GAS)
reporter plasmids and with plasmids carrying a mock vector, a wild type (WT), L163R, or previously
reported STAT1 alleles (two GOF mutant alleles: R274Q and D165H; and a loss-of-function (LOF) mutant
allele: Y701C). Luciferase activity was determined after 16 hours of IFN-g stimulation. Statistical
significance was calculated using the Mann–Whitney U-test. The results are a summary of three respective
experiments. *Po0.01.
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perhaps better mimicked by in vitro
differentiation, are relevant for study.
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Figure 2. Evaluation of IL-17-producing T cells ex vivo in the patient and controls. (a) The percentage
of CD3þ IL-17Aþ cells in nonadherent PBMCs stimulated with PMA/ionomycin for 12 hours, as
measured by flow cytometry. (b) The secretion of IL-17A by whole-blood cells stimulated with PMA/
ionomycin for 48 hours, as determined by ELISA. Horizontal bars indicate means. (c, d) Differentiation of
IL-17-producing T cells in vitro in the patient and a control. Naive CD45RAþ /CD4þ T cells were isolated
from nonadherent PBMCs by immune-magnetic depletion of CD4-CD45ROþ T cells (purity495%)
and stimulated with anti-CD3þ anti-CD28 with or without IL-1bþ IL-23 or IL-1bþ IL-23þ IL-6 for 11
days. (c) The proportion of IL-17A-producing T cells by flow cytometry after 12 hours of PMA/ionomycin
stimulation. (d) The secretion of IL-17A after 48 hours of PMA/ionomycin stimulation as measured by
ELISA.
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